Non-Hodgkin lymphomas represents a heterogeneous group of lymphoproliferative
disorders characterized by different clinical courses, varying from indolent to highly …

The use of functional quantitative biomarkers extracted from routine PET–CT scans to
characterize clinical responses in patients with lymphoma is gaining increased attention …

Consolidative radiation therapy (RT) for advanced-stage diffuse large B-cell lymphoma
(DLBCL) remains controversial, with routine practice continuing to include RT in patients …

Cure rates for primary mediastinal large B-cell lymphoma (PMBCL) have improved with the
integration of rituximab. However, the type of primary therapy and role of radiotherapy (RT) …

This Review focuses on the use of 18 F-fluorodeoxyglucose (18 F-FDG) PET in the
assessment of diffuse large B-cell lymphoma, follicular lymphoma, and peripheral T-cell …

Primary mediastinal B‐cell lymphoma (PMBCL) is a distinct disease closely related to
classical nodular sclerosing Hodgkin lymphoma. Conventional diagnostic paradigms …

Primary mediastinal B-cell lymphoma (PMBL) is a rare type of aggressive lymphoma
typically affecting young female patients. The first-line standard of care remains debated. We …

Diffuse large B-cell lymphoma (DLBCL) encompasses a group of aggressive B-cell non-
Hodgkin lymphomas with striking genetic heterogeneity and variable clinical presentations …

PURPOSE Accurate stratification of patients is an important goal in Hodgkin lymphoma (HL),
but the role of pretreatment clinical risk stratification in the context of positron emission …

Previously considered a subtype of diffuse large B-cell lymphoma (DLBCL), primary
mediastinal B-cell lymphoma (PMBCL) is now recognized by the World Health Organization …